We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of ...

Merus (NASDAQ:MRUS – Get Free Report) had its price target hoisted by research analysts at Citigroup from $89.00 to $97.00 in ...

Needham & Company LLC reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $85.00 price target on the ...

Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on Merus (MRUS – Research Report) today and set a price target of $96.00. The ...

Netherlands-based clinical-stage biotech Merus on Saturday announced interim clinical data as of a July 5, 2024 data cutoff ...

December 05, 2024, 04:52 am ET, BY Momei- Contributor, Stock Traders Daily| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) ...

Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or ...

Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key ...

Guggenheim lowered the firm’s price target on Merus (MRUS) to $109 from $111 and keeps a Buy rating on the shares after the ...

FDA approves Merus' Bizengri for advanced pancreatic adenocarcinoma ... of roughly $16.5 million. Price Action: MRUS stock is down 3.70% at $43.80 at the last check on Thursday.